EPS Reference Time Actual Consensus Previous
2026-11-04 FY2026Q3 PM 0.51 0.43 0.51
2026-07-30 FY2026Q2 PM 0.54 0.43 0.44
2026-05-05 FY2026Q1 PM 0.52 0.34 0.31
2026-02-25 FY2024Q4 PM 0.53 0.39 0.36
2025-11-04 FY2025Q3 PM 0.51 0.32 0.33



Peers Price Chg Day Year Date
Agilent 172.22 -0.70 -0.40% 19.73% Nov/17
Agenus 6.21 -0.08 -1.27% 46.81% Nov/17
Anika Therapeutics 12.85 -0.07 -0.54% 32.89% Nov/17
Arrowhead Research 42.99 -1.22 -2.76% 6.23% Nov/17
Bruker 61.36 0.74 1.22% 43.84% Nov/17
Heron Therapeutics 0.28 -0.002 -0.74% -74.80% Nov/17
Illumina 202.61 4.61 2.33% 66.11% Nov/17
Karyopharm Therapeutics 0.04 0.01 23.08% -99.44% Nov/17
Ligand Pharmaceuticals 293.81 -7.90 -2.62% 41.90% Nov/17
Laboratory Of America 368.24 -4.22 -1.13% 41.73% Nov/17

Indexes Price Day Year Date
USND 24328 -181.37 -0.74% 8.45% Nov/17
US Small-cap 2000 Index 2702 -41.07 -1.50% 15.03% Nov/17

Veracyte traded at $24.23 this Tuesday November 17th, increasing $0.22 or 0.92 percent since the previous trading session. Looking back, over the last four weeks, Veracyte gained 44.68 percent. Over the last 12 months, its price fell by 37.49 percent. Looking ahead, we forecast Veracyte to be priced at 23.78 by the end of this quarter and at 22.21 in one year, according to Trading Economics global macro models projections and analysts expectations.

Veracyte, Inc. is a genomic diagnostics company. The Company, through its scientific platform, which utilizes ribonucleic acid (RNA), whole-transcriptome sequencing combined with machine learning, produces genomic tests. It provides various genomic tests, including Afirma Genomic Sequencing Classifier (GSC), Percepta Bronchial Genomic Classifier, Envisia Genomic Classifier and Afirma Xpression Atlas. It provides GSC tests for thyroid cancer. It provides Percepta Bronchial Genomic Classifier tests for lung cancer. It provides Envisia Genomic Classifier tests for idiopathic pulmonary fibrosis (IPF). Its Afirma Xpression Atlas provides information on gene alterations associated with thyroid cancer, enabling physicians to tailor surgical and treatment decisions at time of diagnosis.